Evidence map›Paper›PMID 39399030›Full record

ArticlemedRxiv : the preprint server for health sciences2025

Ancestry and somatic profile predict acral melanoma origin and prognosis.

Patricia Basurto-Lozada, Martha Estefania Vázquez-Cruz, Christian Molina-Aguilar, Amanda Jiang, Dekker C Deacon, Dennis Cerrato-Izaguirre, Irving Simonin-Wilmer, Fernanda G Arriaga-González, Kenya L Contreras-Ramírez, Emiliano Ferro-Rodríguez and 33 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

43 authors.

Patricia Basurto-LozadaLaboratorio Internacional de Investigación sobre el Genoma Humano, Universidad Nacional Autónoma de México, Santiago de Querétaro, Mexico, 76230.
Martha Estefania Vázquez-CruzLaboratorio Internacional de Investigación sobre el Genoma Humano, Universidad Nacional Autónoma de México, Santiago de Querétaro, Mexico, 76230.
Christian Molina-AguilarLaboratorio Internacional de Investigación sobre el Genoma Humano, Universidad Nacional Autónoma de México, Santiago de Querétaro, Mexico, 76230.
Amanda JiangHuntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, Utah, USA.
Dekker C DeaconHuntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, Utah, USA.
Dennis Cerrato-IzaguirreSubdirección de Investigación Básica, Instituto Nacional de Cancerología (INCan), San Fernando No. 22, Tlalpan, Ciudad de México CP. 14080, Mexico.
Irving Simonin-WilmerLaboratorio Internacional de Investigación sobre el Genoma Humano, Universidad Nacional Autónoma de México, Santiago de Querétaro, Mexico, 76230.
Fernanda G Arriaga-GonzálezLaboratorio Internacional de Investigación sobre el Genoma Humano, Universidad Nacional Autónoma de México, Santiago de Querétaro, Mexico, 76230.
Kenya L Contreras-RamírezLaboratorio Internacional de Investigación sobre el Genoma Humano, Universidad Nacional Autónoma de México, Santiago de Querétaro, Mexico, 76230.
Emiliano Ferro-RodríguezLaboratorio Internacional de Investigación sobre el Genoma Humano, Universidad Nacional Autónoma de México, Santiago de Querétaro, Mexico, 76230.
Jamie BillingtonWellcome Sanger Institute, Hinxton, Cambridgeshire, CB10 1SA, UK.
Eric T DawsonNvidia Corporation, Santa Clara, CA, USA.
J Rene C Wong-RamirezLaboratorio Internacional de Investigación sobre el Genoma Humano, Universidad Nacional Autónoma de México, Santiago de Querétaro, Mexico, 76230.
Johana Itzel Ramos-GalgueraLaboratorio Internacional de Investigación sobre el Genoma Humano, Universidad Nacional Autónoma de México, Santiago de Querétaro, Mexico, 76230.
Alethia Álvarez-CanoSurgical Oncology, Christus Muguerza Alta Especialidad, Monterrey, Nuevo Leon, Mexico.
Dorian Y García-OrtegaSurgical Oncology, Skin, Soft Tissue & Bone Tumors Department, National Cancer Institute, Mexico City, Mexico.
Omar Isaac García-SalinasLaboratorio Internacional de Investigación sobre el Genoma Humano, Universidad Nacional Autónoma de México, Santiago de Querétaro, Mexico, 76230.
Alfredo Hidalgo-MirandaLaboratorio de Genómica del Cáncer, Instituto Nacional de Medicina Genómica (INMEGEN), Mexico City, Mexico.
Mireya Cisneros-VillanuevaLaboratorio de Genómica del Cáncer, Instituto Nacional de Medicina Genómica (INMEGEN), Mexico City, Mexico.
Peter A JohanssonQIMR Berghofer, Brisbane, QLD, Australia.
Héctor Martínez-SaidSurgical Oncology, Skin, Soft Tissue & Bone Tumors Department, National Cancer Institute, Mexico City, Mexico.
Pilar Gallego-GarcíaDigital Genomics Group, Cancer Genomics Program, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
Mark J ArendsEdinburgh Pathology, Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh EH4 2XU, UK.ORCID 0000-0002-6826-8770
Ingrid FerreiraWellcome Sanger Institute, Hinxton, Cambridgeshire, CB10 1SA, UK.
Mark TullettDepartment of histopathology, University Hospitals Sussex, St Richard hospital, Spitalfield lane, Chichester.
Rebeca Olvera-LeónLaboratorio Internacional de Investigación sobre el Genoma Humano, Universidad Nacional Autónoma de México, Santiago de Querétaro, Mexico, 76230.
Louise van der WeydenWellcome Sanger Institute, Hinxton, Cambridgeshire, CB10 1SA, UK.
Martín Del Castillo Velasco HerreraWellcome Sanger Institute, Hinxton, Cambridgeshire, CB10 1SA, UK.
Rodrigo Roldán-MarínDermato-Oncology Clinic, Research Division, Faculty of Medicine, Universidad Nacional Autónoma de México, Mexico City, Mexico.
Helena Vidaurri de la CruzPediatric Dermatology Service, General Hospital of Mexico Dr. Eduardo Liceaga, Ministry of Health. Mexico City, Mexico.
Luis Alberto Tavares-de-la-PazSurgical Oncology, Bajio Regional High Specialty Hospital, Leon, Mexico.
Diego Hinojosa-UgarteSurgical Oncology, Bajio Regional High Specialty Hospital, Leon, Mexico.
Rachel L BeloteThe Ohio State University, Department of Molecular Genetics, Columbus, Ohio, United States.
D Timothy BishopLeeds Institute of Medical Research, University of Leeds, Leeds, UK.
Marcos Díaz-GayDigital Genomics Group, Cancer Genomics Program, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
Ludmil B AlexandrovDepartment of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, USA.ORCID 0000-0003-3596-4515
Yesennia Sánchez-PérezSubdirección de Investigación Básica, Instituto Nacional de Cancerología (INCan), San Fernando No. 22, Tlalpan, Ciudad de México CP. 14080, Mexico.
Gino K InUniversity of Southern California, Keck School of Medicine, Norris Comprehensive Cancer Center, Division of Oncology, Los Angeles, CA, USA.
Richard M WhiteDepartment of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Patrícia A PossikDivision of Basic and Experimental Research, Brazilian National Cancer Institute, Rua Andre Cavalcanti 37, Rio de Janeiro, RJ, 20231-050, Brazil.ORCID 0000-0003-2899-0969
Robert L Judson-TorresHuntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, Utah, USA.
David J AdamsWellcome Sanger Institute, Hinxton, Cambridgeshire, CB10 1SA, UK.
Carla Daniela Robles-EspinozaLaboratorio Internacional de Investigación sobre el Genoma Humano, Universidad Nacional Autónoma de México, Santiago de Querétaro, Mexico, 76230.ORCID 0000-0003-3277-7466

Funding

UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jared P Rutter · 1986 to 2026
$72.6M
Comprehensive identification of germline-somatic interactionsR01CA269919 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Ludmil B Alexandrov, Hannah Kathryn Carter · 2022 to 2026
$2.2M
Nevus associated microRNAs as mediators of BRAF-induced growth arrest and biomarkers of melanoma progressionR01CA229896 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI JUDSON-TORRES, ROBERT LAIRD · 2021 to 2025
$1.8M
Medical Research Council MR/S01473X/1Medical Research Council MR/V000292/1NCI NIH HHS P30 CA042014NCI NIH HHS R01 CA229896NCI NIH HHS R01 CA269919Wellcome Trust
6 · The paper itself

Abstract

Acral melanoma, which is not ultraviolet (UV)-associated, is the most common type of melanoma in several low- and middle-income countries including Mexico. Latin American samples are significantly underrepresented in global cancer genomics studies, which directly affects patients in these regions as it is known that cancer risk and incidence may be influenced by ancestry and environmental exposures. To address this, we characterise the genome and transcriptome of 123 acral melanoma tumours from 92 Mexican patients, a population notable because of its genetic admixture. Compared with other studies of melanoma, we found fewer frequent mutations in classical driver genes such as

Identifiers

PMID39399030
PMCPMC11469390

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.